Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug:38:101019.
doi: 10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15.

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Hannah E Davis  1 , Gina S Assaf  1 , Lisa McCorkell  1 , Hannah Wei  1 , Ryan J Low  1   2 , Yochai Re'em  1   3 , Signe Redfield  1 , Jared P Austin  1   4 , Athena Akrami  1   2
Affiliations

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Hannah E Davis et al. EClinicalMedicine. 2021 Aug.

Abstract

Background: A significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health.

Methods: We conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups (e.g. Body Politic, Long COVID Support Group, Long Haul COVID Fighters) and social media (e.g. Twitter, Facebook). Data were collected from September 6, 2020 to November 25, 2020. We analyzed responses from 3762 participants with confirmed (diagnostic/antibody positive; 1020) or suspected (diagnostic/antibody negative or untested; 2742) COVID-19, from 56 countries, with illness lasting over 28 days and onset prior to June 2020. We estimated the prevalence of 203 symptoms in 10 organ systems and traced 66 symptoms over seven months. We measured the impact on life, work, and return to baseline health.

Findings: For the majority of respondents (>91%), the time to recovery exceeded 35 weeks. During their illness, participants experienced an average of 55.9+/- 25.5 (mean+/-STD) symptoms, across an average of 9.1 organ systems. The most frequent symptoms after month 6 were fatigue, post-exertional malaise, and cognitive dysfunction. Symptoms varied in their prevalence over time, and we identified three symptom clusters, each with a characteristic temporal profile. 85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness. Cognitive dysfunction or memory issues were common across all age groups (~88%). Except for loss of smell and taste, the prevalence and trajectory of all symptoms were similar between groups with confirmed and suspected COVID-19.

Interpretation: Patients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden.

Funding: All authors contributed to this work in a voluntary capacity. The cost of survey hosting (on Qualtrics) and publication fee was covered by AA's research grant (Wellcome Trust/Gatsby Charity via Sainsbury Wellcome center, UCL).

Keywords: COVID recovery; COVID-19; COVID-19 symptoms; Long COVID; Long Hauler; PASC; Patient-Led research; Post Acute COVID; Post-COVID-19 Syndrome; Post-acute Sequelae of COVID-19.

PubMed Disclaimer

Conflict of interest statement

All authors have completed the ICMJE uniform disclosure form and declare: no support from any organization for the submitted work. All authors except HED and GSA declare no financial relationships with any organization that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. HED reports personal fees ($500 speaking fee) from Council for Medical Specialty Society, outside the submitted work. GSA reports personal fees ($1000 speaking fee) from Council for Medical Specialty Society and Karolinska Institute, outside the submitted work.

Figures

Fig 1
Fig. 1
a) Survival function (Kaplan-Meier estimator), characterizing the distribution of disease duration for those who tested Negative (blue) on both diagnostic (RT-PCR/antigen) and antibody tests, those who tested Positive (orange) in either diagnostic or antibody test, and All (green) respondents. The Y axis indicates the probability that symptoms will persist longer than the time specified on the X axis. b) Probability of each symptom severity score over time. c) Average number of reported symptoms over time for those who recovered in less than 90 days (n = 154), or otherwise experienced symptoms for more than 90 days (n = 3505). a-c) In all plots, times are relative to initial symptom onset. Shaded regions represent 95% simultaneous confidence bands.
Fig 2
Fig. 2
Symptom prevalence estimates (non-neuropsychiatric symptoms). Bars represent the percentage of respondents who experienced each symptom at any point in their illness. Symptoms are categorized by the affected organ systems. When all rows in a given panel use the same denominator, the first row, labeled “All,” indicates the percentage of respondents who experienced any symptoms in that category. Error bars are bootstrap 95% confidence intervals. In Fig. 2b, Sexual dysfunction is broken up into male (Sexual dysfunction - M) and female (Sexual dysfunction - F). “Cis M” refers to cisgender males, “Cis F” refers to cisgender females, and cisgender females are further broken down by age group: “Cis F <40″ indicates cisgender females age 39 or younger, “Cis F in 40s” indicates cisgender females age 40 to 49, and “Cis F >49″ indicates cisgender females age 50 or older.
Fig 3
Fig. 3
Symptom prevalence estimates for neuropsychiatric symptoms. Similar to Fig. 2, for neuropsychiatric symptoms, divided into nine sub-categories. Each bar represents the percentage of respondents who experienced that symptom. Error bars are bootstrap 95% confidence intervals.
Fig 4
Fig. 4
Symptom time courses. Plotted time courses represent the estimated probability of experiencing each symptom at each time point, given that recovery has not yet occurred (see Methods). Times are relative to initial illness onset. Symptoms are grouped according to the affected organ systems. Shaded regions show 95% simultaneous confidence bands, estimated separately for each symptom.
Fig 5
Fig. 5
Symptom onset times. Heatmap shows the estimated probability distribution of the onset time for each symptom. White points and error bars show the mean onset time and 95% pointwise confidence intervals. Symptoms are sorted by mean onset time.
Fig 6
Fig. 6
Symptom clusters, based on temporal similarities. Plots (top row) show time courses for the symptoms in each cluster (in gray) and their mean (Cluster 1 in blue, Cluster 2 in orange, Cluster 3 in green). Time courses have been scaled separately for each symptom (by root mean squared amplitude) to visually compare their shapes. The table lists symptoms in each cluster, grouped by the affected organ systems. The heatmap (bottom row) shows time courses for all symptoms, sorted such that similarly shaped time courses are adjacent (see Methods). Columns have been scaled by their maximum amplitudes for visual comparison. Symptoms are numbered according to their table entries.
Fig 7
Fig. 7
Memory and cognitive dysfunction. a) Percentage of respondents in six age groups who experienced different types of memory impairments. b) Same as (a) for cognitive dysfunction. c) Impact of memory and cognitive dysfunction on work (for those who work), for different age groups. Participants were asked to rate the impact by choosing one of the four options “Able, Mildly unable, Moderately unable, and Severely unable”. d) Overall impact of memory and cognitive dysfunction on daily life. Participants to whom the question was not applicable were excluded. Error bars show bootstrap 95% confidence intervals.
Fig 8
Fig. 8
Worsening or relapse of symptoms after physical or mental activity (post-exertional malaise). When does it start (a), how long does it last (b), and how severe is it? (c) (all patients who experienced PEM, n = 3350). Error bars are bootstrap 95% confidence intervals.
Fig 9
Fig. 9
Symptom time courses for participants with COVID-19 confirmed via testing vs. rest of the population. Plots show symptom time courses (similar to Fig. 4) for respondents who were confirmed COVID-positive via diagnostic or antibody testing (orange) vs those without a positive confirmation (untested or tested negative, blue). Shaded regions show simultaneous 95% confidence bands. Symptom names are colored according to the affected organ systems.
Fig 10
Fig. 10
Triggers and experience of relapses. a. Triggers for relapses/worsening of symptoms b. Experience of symptoms over time and relapses. Error bars are bootstrap 95% confidence intervals.
Fig 11
Fig. 11
Remaining symptoms after six months. a) Symptoms remaining after six months. b) Symptoms remaining after six months for respondents still experiencing PEM after six months (orange), respondents not experiencing PEM after six months (green), and respondents who never experienced PEM (blue). c) Average number of symptoms over time for each group in (b). Error bars are bootstrap 95% confidence intervals.
Fig 12
Fig. 12
Return to baseline and work impact. a) Distribution of Fatigue Assessment Scale scores for recovered (n = 257, blue) and unrecovered (n = 3505, yellow) population. The vertical dashed lines indicate the range for “No fatigue”, , , , , , , , , , , , “Fatigue”, , , , , , , , , , , , , and “Extreme” (>=35). Mean values for each distribution are also marked. b) Percentage of participants in each of the three categories. c) Distribution of scores in response to “return to pre-COVID” health baseline, where 0 indicates worst (most different from baseline) and 100 indicates best (most similar to baseline). d) Working status due to COVID-19. Error bars show 95% simultaneous confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Long COVID: cognitive, balance, and retina manifestations.
    Carmona-Cervelló M, León-Gómez BB, Dacosta-Aguayo R, Lamonja-Vicente N, Montero-Alía P, Molist G, Ayet A, Chacón C, Costa-Garrido A, López-Lifante VM, Zamora-Putin V, Liutsko L, García-Sierra R, Fornés A, Moreno-Gabriel E, Massanella M, Muñoz-Moreno JA, Rodríguez-Pérez MC, Mateu L, Prats A, Mataró M, Boigues M, Quirant B, Prado JG, Martínez-Cáceres E, Violán C, Torán-Monserrat P; APC Collaborative Group. Carmona-Cervelló M, et al. Front Med (Lausanne). 2024 Jul 5;11:1399145. doi: 10.3389/fmed.2024.1399145. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39036098 Free PMC article.
  • Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.
    Geng LN, Bonilla H, Hedlin H, Jacobson KB, Tian L, Jagannathan P, Yang PC, Subramanian AK, Liang JW, Shen S, Deng Y, Shaw BJ, Botzheim B, Desai M, Pathak D, Jazayeri Y, Thai D, O'Donnell A, Mohaptra S, Leang Z, Reynolds GZM, Brooks EF, Bhatt AS, Shafer RW, Miglis MG, Quach T, Tiwari A, Banerjee A, Lopez RN, De Jesus M, Charnas LR, Utz PJ, Singh U. Geng LN, et al. JAMA Intern Med. 2024 Jun 7:e242007. doi: 10.1001/jamainternmed.2024.2007. Online ahead of print. JAMA Intern Med. 2024. PMID: 38848477 Free PMC article.
  • Assessing the association between antibody status and symptoms of long COVID: A multisite study.
    Binswanger IA, Palmer-Toy DE, Barrow JC, Narwaney KJ, Bruxvoort KJ, Kraus CR, Lyons JA, Lam JA, Glanz JM. Binswanger IA, et al. PLoS One. 2024 Jun 6;19(6):e0304262. doi: 10.1371/journal.pone.0304262. eCollection 2024. PLoS One. 2024. PMID: 38843198 Free PMC article.
  • The prevalence of long COVID-19 syndrome in hospitalized patients with COVID-19 pneumonia.
    Petrakis V, Rafailidis P, Terzi I, Dragoumani I, Markatou F, Papanas N, Vradelis S, Gouveri E, Panopoulou M, Papazoglou D, Periklis P. Petrakis V, et al. Infez Med. 2024 Jun 1;32(2):202-212. doi: 10.53854/liim-3202-8. eCollection 2024. Infez Med. 2024. PMID: 38827835 Free PMC article.
  • SARS-CoV-2 envelope protein regulates innate immune tolerance.
    Geanes ES, McLennan R, Pierce SH, Menden HL, Paul O, Sampath V, Bradley T. Geanes ES, et al. iScience. 2024 May 15;27(6):109975. doi: 10.1016/j.isci.2024.109975. eCollection 2024 Jun 21. iScience. 2024. PMID: 38827398 Free PMC article.
See all "Cited by" articles

References

    1. Alwan N.A. Surveillance is underestimating the burden of the COVID-19 pandemic. The Lancet. 2020 Sep;396(10252):e24. - PMC - PubMed
    1. 2020. The prevalence of long COVID symptoms and COVID-19 complications [Internet]. Office for national statistics.https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovi... [cited 2020 Dec 17]. Available from:
    1. Petersen M.S., Kristiansen M.F., Hanusson K.D., Danielsen M.E., áSteig B., Gaini S. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clinical Infect Dis [Internet] 2020 doi: 10.1093/cid/ciaa1792. Nov 30 [cited 2020 Dec 17];(ciaa1792). Available from: - DOI - PMC - PubMed
    1. Arnold D.T., Hamilton F.W., Milne A., Morley A., Viner J., Attwood M. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. medRxiv. 2020 Aug 14;2020.08.12.20173526. - PMC - PubMed
    1. Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. Aug 11. - PMC - PubMed